格隆汇2月14日｜13F报告显示：Maverick Capital Ltd.四季度建仓做多谷歌C、应用材料、波士顿科学、 Visa、以及Camden Property。增持台积电、英伟达、GFL Environment、Carvana。清仓Kenvue、美国银 行、AMD、Danaher、以及Insmed。减持Nubank、迪士尼、Merit Medical、Acadia Health、Sherwin- Williams。重仓英伟达、微软、亚马逊、台积电、谷歌C。 ...

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Insights - Acadia Pharmaceuticals anticipates a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding its marketing application for trofinetide to treat Rett syndrome [1][2] Company Overview - Acadia was informed of a negative trend vote on its marketing application for trofinetide, which may delay potential approval in the European Union [2] - The company plans to seek a re-examination of the CHMP opinion once it is formally adopted [2] Product Information - Trofinetide is intended for treating Rett syndrome, a rare neurodevelopmental disorder affecting approximately one in 10,000-15,000 female births globally [3] - The FDA approved trofinetide for treating Rett syndrome in adults and pediatric patients aged two years and older in 2023, marketed as Daybue in the United States [4] Financial Performance - Acadia's shares have increased by 8.6% over the past six months, while the industry has seen a rally of 18.8% [5] - The company expects long-term growth from its products Nuplazid and Daybue, targeting combined net sales of $1.7 billion by 2028, with approximately $1 billion from Nuplazid and $700 million from Daybue [8][9] Market Position - Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, with patent protection until 2038 [10] - In the first nine months of 2025, Nuplazid generated $505.7 million in sales, reflecting a 13% year-over-year increase [10] - Daybue has also shown promising sales, with $281.8 million in sales during the first nine months of 2025, up 12% year-over-year [11] New Product Launch - The FDA recently approved Daybue Stix, an oral solution for treating Rett syndrome, which will be launched in a limited capacity in Q1 2026, followed by broader availability in Q2 2026 [12][13]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Acadia Pharmaceuticals (ACAD) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 50.00%.For the most ...

Core Viewpoint - Fortrea Holdings Inc. (FTRE) is currently viewed as a more attractive option for value investors compared to Acadia Pharmaceuticals (ACAD) based on earnings outlook and valuation metrics [3][7]. Valuation Metrics - FTRE has a forward P/E ratio of 22.52, while ACAD has a forward P/E of 35.71, indicating FTRE is potentially undervalued [5]. - The PEG ratio for FTRE is 0.50, suggesting a favorable growth outlook compared to ACAD's PEG ratio of 6.42, which indicates a less attractive growth valuation [5]. - FTRE's P/B ratio stands at 2.68, compared to ACAD's P/B of 4.83, further supporting FTRE's valuation advantage [6]. Earnings Outlook - FTRE has shown a stronger improvement in its earnings outlook compared to ACAD, contributing to its higher Zacks Rank of 2 (Buy) versus ACAD's 3 (Hold) [3][7].

Core Insights - ACADIA Pharmaceuticals aims to become a leading company in neurological and rare diseases, focusing on delivering meaningful innovations to underserved patients [2][3] Neurological Franchise - The momentum of NUPLAZID is expected to continue driving growth this year and beyond [3] - The company is advancing several pipeline candidates, including a new 5-HT2A agonist, remlifanserin (formerly ACP-204) [3] - Ongoing Phase II programs include ACP-211, a deuterated R-ketamine for major depressive disorder, and potential expansions into essential tremor with ACP-711 and tardive dyskinesia with ACP-271 [3]

Financial Performance - Acadia Pharmaceuticals anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance[6] Corporate Events - The company presented at the J.P. Morgan Healthcare Conference on January 13, 2026[6] - A corporate slide presentation was posted on the company's investor website[6] Regulatory Filings - The report is filed under the Securities Exchange Act of 1934[8] - The company has not elected to use the extended transition period for new financial accounting standards[5] - No emerging growth company status was indicated in the filing[5] - The report includes a Regulation FD disclosure[7] - The financial statements and exhibits are part of the filing[9] - The report was signed by Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer & Secretary[13] Stock Information - Acadia Pharmaceuticals is listed on The Nasdaq Stock Market under the symbol ACAD[5]

Summary of ACADIA Pharmaceuticals FY Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Industry**: Neurological and Rare Diseases - **Conference**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 Core Points and Arguments Company Mission and Strategy - ACADIA aims to deliver meaningful innovation to underserved patients with neurological and rare diseases, focusing on first-in-class or best-in-class products [2][4] - The company is advancing its pipeline with several candidates, including Remlifansirin (5-HT2A agonist) and ACP-211 (deuterated ketamine) for major depressive disorder [3][4] Pipeline Developments - **Neurological Franchise**: - NUPLAZID is expected to continue its momentum, with sales projected to reach $1 billion by 2028 [6][11] - Remlifansirin is anticipated to have a peak sales potential of $4 billion across indications [6] - Upcoming milestones include the initiation of phase two studies for ACP-271 and results for Remlifansirin expected between August and October 2026 [5][25] - **Rare Disease Franchise**: - DAYBUE is projected to achieve $700 million in global sales by 2028, driven by the launch of DAYBUE Sticks and expansion into the EU [14][30] - The company has treated over 2,000 patients with DAYBUE since its launch in 2023, with a 55% persistency rate at 12 months [13] Market Opportunities - There are approximately 1 million Parkinson's patients in the U.S., with 50% expected to develop hallucinations or delusions, presenting a significant market opportunity for NUPLAZID [10] - The company sees a potential growth opportunity in treating essential tremor, which affects about 7 million patients in the U.S. [23] Commercial Strategy - ACADIA plans to increase its commercial field force for NUPLAZID by 30% and leverage AI for better targeting and engagement [12][8] - The company is focused on expanding its presence in international markets, with DAYBUE already approved in three markets and anticipated approval in Europe [9][27] Financial Projections - Combined net sales for NUPLAZID and DAYBUE are projected to reach $1.7 billion by 2028 [6][30] - The company expects to see an uptick in operating expenses due to investments in commercial expansion and pipeline development [32][33] Additional Important Content - The company is committed to utilizing AI across various functions, including R&D and regulatory processes, to enhance efficiency and decision-making [7][9] - ACADIA is exploring business development opportunities in rare diseases beyond neurology, with a focus on late-stage products [34][35] - The company emphasizes the importance of patient-centric approaches in its clinical trials and product development [18][21] This summary encapsulates the key points discussed during the conference call, highlighting ACADIA Pharmaceuticals' strategic direction, pipeline developments, market opportunities, and financial outlook.

J.P. Morgan Healthcare Conference January 13, 2026 Catherine Owen Adams Chief Executive Officer 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," ...